drugset / Trial / NCT00825084

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

NCT00825084

Phase 1 Completed 45 enrolled Pfizer Medivation, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to characterize the pharmacokinetics of single and multiple oral doses of Dimebon in Japanese healthy subjects. This study is also to evaluate the safety and tolerability of single and multiple oral doses of Dimebon in Japanese healthy subjects. The secondary objective of this study is to compare the pharmacokinetics, safety and tolerability of single and multiple oral doses of Dimebon in Japanese and Western healthy subjects.

Timeline

Start
2009-02
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Latrepirdine Small molecule 5 mg Oral
Subject Latrepirdine Small molecule 10 mg Oral
Subject Latrepirdine Small molecule 20 mg Oral